Description
The NanoAssemblr® Blaze™ and Blaze+™ allow rapid scaling of nanoparticle formulations for late preclinical development. The systems can manufacture between 20 mL and 10 L of formulation which allows researchers to use the Blaze and Blaze+ for preclinical toxicology testing and for early Chemistry, Manufacturing and Controls (CMC) studies.
A candidate drug must be shown to be both potent and non-toxic. As the demands for data in larger animal models increase, process development for nanomedicine production becomes increasingly important. With NxGen™ technology on the NanoAssemblr® Blaze, these important studies can be conducted efficiently with a process that mirrors a clinical scale implementation. In addition, the Blaze+ Upgrade allows the formulation of volumes from 1 L to 10 L to enable late preclinical experiments and process development activities to be performed in house at lower cost, including stability studies and evaluation of upstream and downstream procedures such as tangential flow filtration (TFF).
Features:- The Scalable Power of NxGen® - Advance drug candidates by scaling up to the NxGen 400 and NxGen 500 cartridges—the same ones used on the GMP System.
- Expanded Process Development Capabilities - Continuous flow pumping and in-line pressure monitoring provide an efficient platform for process development.
- Outstanding Reproducibility - Exquisite batch-to-batch reproducibility enables the identification of critical quality attributes from raw material supply to the final manufacturing steps.
- Intuitive Workflow - Easy-to-use interface, built-in checklists, saved recipes and complete run history ensures new users are quickly able to perform the studies they need.